SGT 003
Alternative Names: SGT-003Latest Information Update: 11 Feb 2026
At a glance
- Originator Solid Biosciences
- Class Gene therapies
- Mechanism of Action Dystrophin replacements; Gene transference
-
Orphan Drug Status
Yes - Duchenne muscular dystrophy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Duchenne muscular dystrophy
Most Recent Events
- 09 Feb 2026 Solid Biosciences aligns with the US FDA on the overall study design for the phase III IMPACT DUCHENNE trial
- 09 Feb 2026 Solid Biosciences plans for additional meetings with the US FDA for Duchenne muscular dystrophy to align on a potential accelerated approval pathway for SGT 003, in 1H 2026
- 09 Feb 2026 Updated adverse events data from the phase I/II INSPIRE DUCHENNE trial in Duchenne muscular dystrophy released by Solid Biosciences